


Supplementary Figure 1: Overall survival in cohorts characterized by number of completed cycles of ipilimumab + nivolumab in mUM



Supplementary Table 1: Participating centers in retrospective mUM cohort treated with combination ipilimumab + nivolumab

Institution	N (%)
Memorial Sloan Kettering Cancer Center	21 (24%)
University of California San Francisco	10 (11%)
Moffitt Cancer Center	9 (10%)
University of Washington	8 (9%)
Columbia University Medical Center	7 (8%)
Cleveland Clinic	6 (7%)
Northwestern University	5 (6%)
Roswell Park Comprehensive Cancer Center	5 (6%)
Thomas Jefferson University (Sidney Kimmel Medical College)	4 (4%)
UPMC Hillman Cancer Center	4 (4%)
University of Chicago	3 (3%)
Penn State Health Milton S. Hershey Medical Center	3 (3%)
Vanderbilt University	2 (2%)
Massachusetts General Hospital	2 (2%)